Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$2.40 +0.8%	$2.07	$0.77 ▼ $4.08	$331.87M	1.42	958,292 shs	1.26 million shs
FHTX Foghorn Therapeutics	$4.72 -0.6%	$4.25	$2.94 ▼ $10.25	$263.09M	3.05	143,149 shs	162,682 shs
FUSN Fusion Pharmaceuticals	$21.55	$21.50	$2.31 ▼ $21.60	$1.83B	-0.69	1.69 million shs	N/A
RLYB Rallybio	$0.31 -6.0%	$0.32	$0.22 ▼ $1.60	$12.75M	-1.24	123,196 shs	237,361 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	0.00%	-0.41%	+14.83%	+1.27%	+118.18%
FHTX Foghorn Therapeutics	0.00%	+9.26%	+14.01%	+11.85%	-10.94%
FUSN Fusion Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
RLYB Rallybio	0.00%	-5.40%	-6.92%	-49.59%	-79.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPX Compass Therapeutics	3.5468 of 5 stars	4.6	1.0	0.0	0.0	2.7	5.0	0.0
FHTX Foghorn Therapeutics	1.7066 of 5 stars	3.6	2.0	0.0	0.0	0.0	1.7	0.6
FUSN Fusion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	3.0382 of 5 stars	3.0	5.0	0.0	0.0	0.0	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPX Compass Therapeutics	3.11	Buy	$13.13	446.88% Upside
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	156.89% Upside
FUSN Fusion Pharmaceuticals	0.00	N/A	N/A	N/A
RLYB Rallybio	2.00	Hold	$10.00	3,162.64% Upside

Current Analyst Ratings Breakdown

Latest CMPX, FUSN, RLYB, and FHTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
4/30/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/28/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/23/2025	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/23/2025	FHTX Foghorn Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform	$9.00
4/23/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$9.00
4/22/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/21/2025	CMPX Compass Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPX Compass Therapeutics	$850K	390.44	N/A	N/A	$0.91 per share	2.64
FHTX Foghorn Therapeutics	$22.60M	11.64	N/A	N/A	($0.82) per share	-5.76
FUSN Fusion Pharmaceuticals	$2.07M	885.53	N/A	N/A	$3.07 per share	7.02
RLYB Rallybio	$640K	19.93	N/A	N/A	$1.49 per share	0.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPX Compass Therapeutics	-$49.38M	-$0.41	N/A	N/A	N/A	N/A	-42.47%	-38.31%	8/11/2025 (Estimated)
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	N/A	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
FUSN Fusion Pharmaceuticals	-$94.90M	-$1.42	N/A	N/A	N/A	-4,136.55%	-48.74%	-36.87%	N/A
RLYB Rallybio	-$57.78M	-$1.09	N/A	N/A	N/A	-5,682.19%	-72.31%	-64.78%	8/14/2025 (Estimated)

Latest CMPX, FUSN, RLYB, and FHTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
5/8/2025	Q1 2025	RLYB Rallybio	-$0.21	-$0.21	N/A	-$0.21	N/A	$0.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
FUSN Fusion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPX Compass Therapeutics	N/A	8.33	8.33
FHTX Foghorn Therapeutics	N/A	3.16	3.16
FUSN Fusion Pharmaceuticals	0.21	10.64	10.64
RLYB Rallybio	N/A	14.68	14.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPX Compass Therapeutics	68.43%
FHTX Foghorn Therapeutics	61.55%
FUSN Fusion Pharmaceuticals	72.85%
RLYB Rallybio	90.34%

Insider Ownership

Company	Insider Ownership
CMPX Compass Therapeutics	29.80%
FHTX Foghorn Therapeutics	7.58%
FUSN Fusion Pharmaceuticals	7.75%
RLYB Rallybio	8.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
FUSN Fusion Pharmaceuticals	101	85.06 million	78.47 million	Optionable
RLYB Rallybio	40	41.61 million	37.99 million	Not Optionable

CMPX, FUSN, RLYB, and FHTX Headlines

Recent News About These Companies

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

June 13, 2025 | finance.yahoo.com

Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook

May 24, 2025 | investing.com

Rallybio shareholders elect directors, ratify auditor

May 18, 2025 | uk.investing.com

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 9, 2025 | finance.yahoo.com

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

April 29, 2025 | finance.yahoo.com

Jones Trading Downgrades Rallybio (RLYB)

April 15, 2025 | msn.com

Rallybio downgraded to Hold from Buy at JonesResearch

April 14, 2025 | markets.businessinsider.com

Rallybio downgraded to In Line from Outperform at Evercore ISI

April 12, 2025 | markets.businessinsider.com

Rallybio (RLYB) was downgraded to a Hold Rating at H.C. Wainwright

April 10, 2025 | markets.businessinsider.com

Rallybio Stock Short Interest Report | NASDAQ:RLYB | Benzinga

April 9, 2025 | benzinga.com

Rallybio discontinues RLYB212 program

April 9, 2025 | markets.businessinsider.com

Rallybio sinks as it drops RLYB212 for prevention of FNAIT

April 9, 2025 | thepharmaletter.com

HC Wainwright & Co. Downgrades Rallybio (RLYB)

April 9, 2025 | msn.com

RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks

April 9, 2025 | zacks.com

Citizens JMP downgrades Rallybio on RLYB212 discontinuation

April 9, 2025 | markets.businessinsider.com

JMP Securities downgrades Rallybio (RLYB) to a Hold

April 9, 2025 | theglobeandmail.com

Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints

April 8, 2025 | benzinga.com

Rallybio Discontinues Development of Treatment for Prevention of Rare Immune Disorder

April 8, 2025 | marketwatch.com

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

April 8, 2025 | finance.yahoo.com

Rallybio reports Q4 EPS (25c), consensus (30c)

March 13, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX, FUSN, RLYB, and FHTX Company Descriptions

Compass Therapeutics NASDAQ:CMPX

$2.40 +0.02 (+0.84%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.40 0.00 (-0.21%)

As of 06/20/2025 07:39 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Foghorn Therapeutics NASDAQ:FHTX

$4.72 -0.03 (-0.63%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$4.70 -0.01 (-0.32%)

As of 06/20/2025 04:11 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fusion Pharmaceuticals NASDAQ:FUSN

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.

Rallybio NASDAQ:RLYB

$0.31 -0.02 (-6.01%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$0.32 +0.01 (+4.08%)

As of 06/20/2025 06:03 PM Eastern

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time